Author/Editor     Obradović, Marko
Title     Farmakoekonomika zdravil za zdravljenje Alzheimerjeve in Parkinsonove bolezni
Translated title     Pharmacoeconomics of drugs used in the treatment of Alzheimer's and Parkinson's disease
Type     članek
Source     2331505
Publication year     2008
Volume     str. 90-98
Language     slv
Abstract     V uvodu je jedrnato predstavljena metodologija farmakoekonomskih raziskav. Temu sledijo izsledki raziskav, ki so ocenjevale ekonomske posledice obeh bolezni za družbo, ter trenutne informacije, ki so na voljo o klinični in stroškovni učinkovitosti zdravil za zdravljenje Alzheimerjeve in Parkinsonove bolezni. Raziskave kažejo, da je družbeno breme Alzheimerjeve in Parkinsonove bolezni veliko. Bolezni mooeno vplivata ne zgolj na bolnike, temveč tudi na njihove skrbnike. Letni stroški na bolnika z Alzheimerjevo oz. Parkinsonovo boleznijo izredno narastejo, kadar se stanje bolnika poslabša. Obstoječa zdravila, ki se uporabljajo za zdravljenje Alzheimerjeve bolezni, imajo skromne učinke. Trenutno primanjkuje raziskav, ki bi vrednotile vpliv teh zdravil na kakovost življenja bolnikov in skrbnikov, kar onemogoča sprejetje oprijemljivih zaključkov o stroškovni učinkovitosti teh zdravil. Pri zdravljenju Parkinsonove bolezne je klinično pomembna učinkovitost zdravil dokazana, kljub temu pa obstaja potreba po večjih in dolgotrajnejših kliničnih raziskavah. Obstoječe farmakoekonomske analize kažejo, da novejša zdravila za zdravljenje Parkinsonove bolezni kljub dodatnim stroškom za zdravila potencialno znižajo celokupne stroške z družbenega vidika.Methodology used in pharmacoeconomic research is briefly described in the introductory section, followed by the results of cost-ofillness studies and present information on clinical effectiveness and cost-effectiveness of drugs used in the treatment of Alzheimerćs and Parkinsonćs disease. Studies show that the burden of Alzheimerćs and Parkinsonćs disease is substantial. Not only patients but also caregivers are strongly affected by the diseases. Yearly costs per patient with Alzheimerćs or Parkinsonćs disease increase sharply as disease progresses. Presently available drugs for the treatment of Alzheimerćs disease show only modest effect. Moreover, there is a lack of research evaluating the effect of drugs on the quality of life of these patients, so no firm conclusions about the cost-effectiveness of these drugs can be reached. Effectiveness of drugs used in the treatment of Parkinsonćs disease is clinically relevant, nevertheless, large and long-term studies are needed. The existing pharmacoeconomics studies show that from societal perspective, additional cost of new drugs for the treatment of Parkinsonćs disease is potentially outweighted by other savings.
Keywords     Alzheimerjeva bolezen
Parkinsonova bolezen
zdravljenje
farmakoekonomika
družbeno breme